Post on 11-Mar-2019
PT INDOFARMA, Tbk
JL. INDOFARMA No. 1 ,
Gandasari – Cibitung, 17350
Bekasi – INDONESIA
TELP 62 21 8832 3971
FAX 62 21 8832 3972
DIREKSI PERSEROAN
Dari Kiri ke Kanan :
Direktur Operasi & Pengembangan : Bambang Solihin Irianto
Direktur Utama : Djakfarudin Junus
Direktur Produksi : Kosasih
Direktur Riset dan Pemasaran : Elfiano Rizaldi
Direktur Keuangan & SDM : John Guntar Sebayang
AGENDA
1. INSIGHT FROM HEALTH CARE & PHARMA
MARKET
2. PHARMA BUSINESS OUTLOOK
3. INDOFARMA PERFORMANCE IN FIVE YEARS
4. INDOFARMA BUSINESS PLAN IN BRIEF
1. INSIGHT FROM HEALTH CARE & PHARMA MARKET
Pharma industry & boundary industries
MEDICINE BASEDTHERAPIES
Device basedTherapies
Medical devicesand equipment
• Local ETHs & OTCs are growing fast across all
channels
• Retail sector continue to grow
• Unaudited sector still fuel market growth
• Dispensing doctors
• Clinics channels
• Government push for full implementation of the Universal Health Coverage Program
• PT. ASKES will be transformed into BPJS-1 starting 01-01-2014, followed by PT. Jamsostek to become BPJS-2
• New drug registration tend to be longer than previous years
• Indonesia is expected to lead economic growth in six Southeast Asian countries over the next five years despite the slowdown in the global economy
• Annual GDP growth rate remained steady at 6.3% in 2011, the highest amongst ASEAN’s
• Around 2% of income spent on health care and healthcare spending will continue to be out-of-pocket
• Local companies keep dominating the market
• MNCs are increasingly viewing the market as an
attractive investment thru organic and inorganic
growth strategy
• Local players are expanding the production and R&D
capacity
Dynamics
Government InterventionMacro-economics
Channels MNC and Local
IPEX 3Q11 Specially Prepared For IMS
2. PHARMA BUSINESS OUTLOOKIn
do
nesi
a -
Mark
et
Dyn
am
ics
Growth in all market
Ethical product is dominant in panel market meanwhile OTC product is dominant in non-panel market
2. PHARMA BUSINESS OUTLOOK
Indonesian Pharmaceutical Market 2006 – 2014 (est.)
2.3 2.53.0
3.43.7
4.24.7
5.4
6.1
0
1
2
3
4
5
6
7
2006 2007 2008 2009 2010 2011 2012 2013 2014
CAGR = 12.4%
CAGR = 13.4%
Source : IMS
2. PHARMA BUSINESS OUTLOOK
CAGR = Composite Annual Growth RatePasar Farmasi Indonesia akan tumbuh sangat atraktif sebesar 13,4%
Branded (includes innovators and branded generic) further
dominates, however unbranded generic is growing faster (MAT 3Q)
8.44 7.26 6.92 7.98 8.12
91.56 92.74 93.08 92.02 91.88
0%
20%
40%
60%
80%
100%
MAT 3Q07 MAT 3Q08 MAT 3Q09 MAT 3Q10 MAT 3Q11
GENERIC BRANDED
BIO IDR MAT 3Q07 MAT 3Q08 MAT 3Q09 MAT 3Q10 MAT 3Q11TOTAL MANUF 25,538 29,693 34,501 37,283 42,172TOTAL GROWTH % 16.27 16.19 8.06 13.11GENERIC 2,156 2,159 2,389 2,975 3,427GENERIC GROWTH % 0.12 10.68 24.51 15.18BRANDED 23,382 27,534 32,112 34,308 38,745
BRANDED GROWTH % 17.76 16.62 6.84 12.94
2. PHARMA BUSINESS OUTLOOK
Positive trend of ethical generic market means Opportunities for Indofarma to thrive
2. PHARMA BUSINESS OUTLOOK
2. PHARMA BUSINESS OUTLOOKTOP 20 ETHICAL MANUFACTURERS
Value (Rp) % Market Share % Growth
ETHICAL 25,045,924,709,989 100.00 9.92
1 SANBE 1,946,837,514,614 7.77 4.12
2 KALBE FARMA 1,839,343,864,518 7.34 7.77
3 DEXA MEDICA 1,242,850,039,866 4.96 13.67
4 FAHRENHEIT 892,201,290,500 3.56 9.04
5 PFIZER 860,524,903,532 3.44 -9.27
6 SANOFI-AVENTIS 832,780,590,520 3.33 12.19
7 INTERBAT 787,330,605,300 3.14 7.42
8 KIMIA FARMA 729,284,621,183 2.91 2.61
9 NOVARTIS 669,543,238,311 2.67 22.51
10 DANKOS 625,287,487,100 2.50 3.07
11 HEXPHARM JAYA 595,298,204,968 2.38 5.29
12 BAYER INDONESIA 565,055,659,284 2.26 7.06
13 GLAXOSMITHKLINE PH 557,510,010,242 2.23 16.26
14 INDOFARMA 553,016,757,351 2.21 22.27
15 OTTO 475,762,335,412 1.90 23.03
16 OTSUKA 423,246,283,347 1.69 3.06
17 PHAROS INDONESIA 418,003,175,235 1.67 15.15
18 SOHO 399,428,262,536 1.59 36.48
19 ASTRAZENECA 379,386,926,123 1.51 7.08
20 B.INGELHEIM 362,459,182,800 1.45 15.22
NO MANUFITMA - MOVING ANNUAL TOTAL Q4 2011 IN VALUE
2. PHARMA BUSINESS OUTLOOKGenerics are driven more by price than unit
Value (Rp) % Market Share % Growth
ETHICAL 25,045,924,709,989 100.00 9.92
GENERIC 2,965,778,179,632 11.84 18.73
1 INDOFARMA 521,569,470,930 17.59% 26.11
2 KIMIA FARMA 416,786,284,217 14.05% 2.72
3 HEXPHARM JAYA 415,156,295,188 14.00% 10.59
4 DEXA MEDICA 305,411,545,077 10.30% 19.60
5 GENERIC MANUF. 269,742,235,648 9.10% 23.28
6 WIDATRA BHAKTI 211,167,655,054 7.12% 17.61
7 BERNOFARM 163,302,690,043 5.51% 41.19
8 PHAPROS 150,364,598,714 5.07% 61.82
9 KALBE FARMA 101,049,983,368 3.41% 51.48
10 NOVELL PHARM 67,454,451,038 2.27% 15.74
11 COMBIPHAR 31,711,734,150 1.07% 11.33
12 MEIJI 26,436,649,250 0.89% -6.55
13 JANSSEN 24,246,960,000 0.82% 64.23
14 PRAFA 23,098,255,425 0.78% -2.14
15 HARSEN 21,869,292,281 0.74% -8.28
16 IKAPHARMINDO 19,823,003,960 0.67% 21.55
17 ETHICA 18,545,658,165 0.63% 16.70
18 FERRON PAR PHARM 18,153,858,500 0.61% -22.51
19 NEWPORT 16,270,400,600 0.55% -5.70
20 OTTO 15,032,952,112 0.51% 724.44
NO MANUFITMA - MOVING ANNUAL TOTAL Q4 2011 IN VALUE
2. PHARMA BUSINESS OUTLOOK1st GENERIC MARKET LEADER INDONESIA IN 5th YEARS
0
100,000
200,000
300,000
400,000
500,000
600,000
2007 2008 2009 2010 2011
INDOFARMA
KIMIA FARMA
HEXPHARM JAYA
DEXA MEDICA
GENERIC MANUF.
WIDATRA BHAKTI
BERNOFARM
PHAPROS
KALBE FARMA
NOVELL PHARM
Sumber : IMS
Dalam Jutaan Rp
FINANCIAL PERFORMANCE
1. IN FIVE YEARS
2. Q1 2012 VS Q1 2011
3. FINANCIAL REPORT AUDITED 2011
(REISSUE VERSION) 26 Apr 2012
FINANCE DIRECTOR
3.a.1. INDOFARMA PERFORMANCE IN FIVE YEARS
Sales, COGS , Nett Profit, Financial Ratio, Assets & Equity
2007 2008 2009 2010 2011
Total Sales 1,273 1,479 1,125 1,048 1,204
-
500
1,000
1,500
2,000
2007 2008 2009 2010 2011
HPP 77% 77% 73% 70% 67%
62%64%66%68%70%72%74%76%78%80%
HPP
2007 2008 2009 2010 2011
Laba Usaha 45 63 46 56 92
Laba Bersih 11 5 2 13 37
-
10
20
30
40
50
60
70
80
90
100
3.a.1. INDOFARMA PERFORMANCE IN FIVE YEARS
Sales, COGS , Nett Profit, Financial Ratio, Assets & Equity
3.a.2 INDOFARMA PERFORMANCE Q1 2012 VS Q1 2011
Sales, COGS & Nett Profit
118.88
168.82
0
50
100
150
200
Q1 2011 Q1 2012
SALES
64.8%
58.3%
55.0%
60.0%
65.0%
70.0%
Q1 2011 Q1 2012
COGS
-17.1%
0.1%
-20.0%
-15.0%
-10.0%
-5.0%
0.0%
5.0%
Q1 2011 Q1 2012
NETT PROFIT
milyar rupiah
140,099,332
(20,372,167,877)
3.a.3 PENERBITAN KEMBALI LAPORAN KEUANGAN AUDITED TAHUN 2011
(RE ISSUE VERSION) 26 APRIL 2012
1. Penambahan pengungkapan kembali dan reklasifikasi akun terkait perubahan PSAK
yang efektif berlaku pada 1 Januari 2011 dengan penambahan pengungkapan
tersendiri,
2. Penambahan pengungkapan kebijakan estimasi umur ekonomis aset tetap,
3. Perbaikan redaksional Catatan Laporan Keuangan No. 39 tentang Kuasi
Reorganisasi, perubahan yang terjadi adalah dari Tambahan Modal Disetor menjadi
Selisih Penilaian Aset yang telah disesuaikan dengan Laporan Posisi Keuangan hal 2,
4. Penambahan pengungkapan atas pihak berelasi dan tidak berelasi pada Laporan Posisi
Keuangan (sesuai dengan PSAK No. 7 Revisi 2009) yang pada awalnya pengungkapan
Laporan Posisi Keuangan disajikan menurut IFRS,
5. Perbaikan subjumlah hutang usaha – pihak berelasi telah diperbaiki yang pada
awalnya bernilai Rp131 Milyar menjadi Rp127 Miliar dengan rincian yang ada,
6. Perbaikan subjumlah piutang usaha – pihak tidak berelasi telah diperbaiki dengan
rincian sebagai berikut :
Posisi Sebelumnya Seharusnya
30 September 2011 166 milyar 169 milyar
31 Desember 2010 15 milyar 10 milyar
1 Januari 2010 4,7 milyar 5,8 milyar
7. Perubahan tanggal pada lampiran Laporan Posisi Keuangan – Induk Perusahaan dari
30 September 2011 menjadi 31 Desember 2011
cGMPIndofarma senantiasa mengupdatefasilitas produksi sesuai denganCurrent Good Manufacturing Practices (cGMP)
Pada Tahun 2009 – 2010 Indofarmamenginvestasikan 45 milyar untukupgrade fasilitas produksi.
ISO 9001 : 2008Indofarma telah mengupgradeSistem Manajemen Mutu ISO 9001 : 2008.
3.b. INDOFARMA PERFORMANCE IN FIVE YEARSCOMPLIANCE cGMP & ISO 9001 : 2008 IN 5thYEARS
0
2
4
6
8
10
12
2007 2008 2009 2010 2011
Product launch
3.b. INDOFARMA PERFORMANCE IN FIVE YEARS
Number of New Products in the Past 5 Years
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
PHARMA INDUSTRY : FUTURE DEVELOPMENT
BUSINESS DEVELOPMENT
CORE COMPETENCE
CORE BUSINESS
PHAMA INDUSTRY
GENERICS
COMMODITY GENERICS
SUPER GENERICS
BIOGENERICS
FUTURE PRODUCTS
BRANDED GENERICS & OTC
NON MEDICINE (HERBAL)
BOUNDARIES INDUSTRY
NEUTRACEUTICALS
COSMECEUTICALS
MEDICAL DEVICES
UU No 40 Tahun 2004
Sistem Jaminan SosialNasional
JaminanKesehatan
JaminanKecelakaan
Kerja
JaminanHari Tua
JaminanPensiun
JaminanKematian
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
S J S N
PayerProvider &Pharma
Price controlIncrease volume
Economic aspect
Social aspect
Investment
Technology aspect
Balance between Payer vs Provider & Pharma
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
Leading Therapeutical Class I by Value – Ethical Market 2011
45,31 M
51,67 M
114,75 M
308,37 M
615,94 M
823,10 M
878,78 M
905,62M
938,08 M
1,25 T
1,49 T
1,50 T
2,28 T
3,46 T
3,70 T
6,69 T
0 2,000,000,000,000 4,000,000,000,000 6,000,000,000,000 8,000,000,000,000
PARASITOLOGY
DIAGNOSTIC AGENTS
VARIOUS
SENSORY ORGANS
SYSTEMIC HORMONES
ANTINEOPLAST+IMMUNOMODUL
DERMATOLOGICALS
G.U.SYSTEM & SEX HORMONES
BLOOD + B.FORMING ORGANS
MUSCULO-SKELETAL SYSTEM
HOSPITAL SOLUTIONS
RESPIRATORY SYSTEM
NERVOUS SYSTEM
CARDIOVASCULAR SYSTEM
ALIMENTARY T.& METABOLISM
SYSTEMIC ANTI-INFECTIVES
Potential therapeutical class to develop market and product
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
Leading Therapeutical Class I by Value – Generic Market 2011
473,04 M
17,60 M
19,93 M
24,01 M
32,18 M
44,75 M
68,39 M
90,60 M
102,80 M
107,12 M
113,49 M
248,84 M
267,68 M
351,59 M
374,97 M
1,10 T
0 400,000,000,000 800,000,000,000 1,200,000,000,000
DIAGNOSTIC AGENTS
VARIOUS
PARASITOLOGY
SENSORY ORGANS
G.U.SYSTEM & SEX HORMONES
BLOOD + B.FORMING ORGANS
RESPIRATORY SYSTEM
ANTINEOPLAST+IMMUNOMODUL
MUSCULO-SKELETAL SYSTEM
DERMATOLOGICALS
SYSTEMIC HORMONES
ALIMENTARY T.& METABOLISM
HOSPITAL SOLUTIONS
NERVOUS SYSTEM
CARDIOVASCULAR SYSTEM
SYSTEMIC ANTI-INFECTIVES
Potential therapeutical class to develop generic market and product
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
Perbandingan Peraturan BUMN vs BUMS
BUMN
UU PT
SWASTA
UU PASAR MODAL
UU SEKTORAL
UU BUMN
UU KEUANGAN NEGARA
UU PERBENDAHARAAN NEGARA
UU TIPIKOR
UU PEMERIKSAAN PENGEL & Tg
JAWAB KEU.NEG
BUMN 8 REGULASI 3 SWASTA
BUMN diwajibkan untuk mematuhi peraturan/ketentuan yang jumlah dan lingkupnya lebih banyak daripadaswasta. Kondisi ini menjadikan BUMN tidak memiliki LEVEL OF PLAYING FIELD yang sama dengan SWASTA.
Tidak Adanya Equal Level Of Playing Field Bagi BUMNDari Sisi Peraturan
Sumber: Biro Hukum Kementerian BUMN RI
4. a INDOFARMA BUSINESS PLAN IN BRIEF - BUSINESS ASSUMPTION
Strategic Initiative
Inhouse
Marketing Alliance
Source Alliance
• Penunjukan sebagai Pusat Extract Nasional
• Indomach (Produksi Mesin)• Rating Independent
• Kerjasama Produksi dan PemasaranRadiofarmaka
• Memperluas pasar expor regional diAsean (Vietnam. Kamboja. Philipina)
• Bahan Baku serta Toll Manufacturing• Kerjasama Penelitian : BPPT. LIPI.
Perguruan Tinggi• Sinergi dengan Rumah Sakit BUMN
4. b INDOFARMA BUSINESS PLAN IN BRIEF – FINANCIAL PROJECTION
Sales, COGS , Income from Operation & Nett Income 2013 - 2017
4,254
2,754
522
383
-
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2013 2014 2015 2016 2017
Penjualan
Harga Pokok Penjualan
Laba Usaha
Laba Bersih
Dalam milyar rupiah